Foghorn Therapeutics Inc.(FHTX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,845 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
FHTX Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Foghorn Therapeutics Inc. (FHTX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores FHTX at 16.1/100 on a 32-signal composite quality model, placing it at rank #2,845 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include free cash flow (4.1) and earnings quality (5.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 5.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Foghorn Therapeutics Inc. reports quarterly revenue of $16.1M, net income of $-7.2M, free cash flow of $-17.9M. Top institutional holders of FHTX by reported 13-F value include Flagship Pioneering, BVF, FMR, based on the most recent SEC filings. FHTX trades on the Nasdaq exchange and files with the SEC under CIK 1822462. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate FHTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Foghorn Therapeutics Inc. directly from SEC EDGAR. Foghorn Therapeutics Inc.'s 13F Pro composite quality score has ranged between 9 and 42 since 2021, currently 16.1 — a declining long-term trajectory across 67 quarterly and live scoring snapshots.
Revenue
Q2 2026
$16.1M
Net Income
Q2 2026
$-7.2M
Free Cash Flow
Q2 2026
$-17.9M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+36.8% YoYNet Income
+14.2% YoYOperating Income
+15.9% YoYEPS (Diluted)
+25.3% YoYTotal Assets
-30.2% YoYTotal Debt
Op. Cash Flow
+14.2% YoYFree Cash Flow
+15.0% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $30.9M +36.8% | $22.6M -33.8% | $34.2M +77.6% | $19.2M +1357.8% | $1.3M +206.7% | $430.0K |
| Net Income | $-74.3M +14.2% | $-86.6M +12.0% | $-98.4M +9.6% | $-108.9M -7.5% | $-101.3M -47.3% | $-68.8M |
| Operating Income | $-86.4M +15.9% | $-102.7M +4.8% | $-107.9M +7.9% | $-117.1M -16.3% | $-100.7M -47.0% | $-68.5M |
| EPS (Diluted) | $-1.18 +25.3% | $-1.58 +32.5% | $-2.34 +10.7% | $-2.62 +4.0% | $-2.73 +56.2% | $-6.23 |
| Total Assets | $198.1M -30.2% | $284.0M -0.7% | $285.9M -29.4% | $404.9M -22.1% | $519.8M +103.4% | $255.6M |
| Total Debt | — | — | — | — | $0.00 -100.0% | $19.7M |
| Operating Cash Flow | $-86.1M +14.2% | $-100.4M +15.0% | $-118.1M -161.0% | $193.6M +485.3% | $-50.3M -60.6% | $-31.3M |
| Free Cash Flow | $-86.1M +15.0% | $-101.3M +15.1% | $-119.3M -162.0% | $192.4M +459.2% | $-53.6M -12.8% | $-47.5M |
Get alerted when FHTX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Foghorn Therapeutics Inc. including:
Top Institutional Holders of FHTX
Flagship Pioneering Inc.
$61.8M12,674,120 shBVF INC/IL
$28.5M5,842,000 shFMR LLC
$27.8M5,705,958 shDEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$21.4M4,394,367 shBlackRock, Inc.
$12.8M2,626,832 shRAYMOND JAMES FINANCIAL INC
$12.2M2,489,978 shEuclidean Capital LLC
$7.7M1,573,761 shVANGUARD CAPITAL MANAGEMENT LLC
$7.3M1,494,611 shGEODE CAPITAL MANAGEMENT, LLC
$4.4M910,866 shSiren, L.L.C.
$3.5M720,720 sh
| Fund | Value | Shares |
|---|---|---|
| Flagship Pioneering Inc. | $61.8M | 12,674,120 |
| BVF INC/IL | $28.5M | 5,842,000 |
| FMR LLC | $27.8M | 5,705,958 |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | $21.4M | 4,394,367 |
| BlackRock, Inc. | $12.8M | 2,626,832 |
| RAYMOND JAMES FINANCIAL INC | $12.2M | 2,489,978 |
| Euclidean Capital LLC | $7.7M | 1,573,761 |
| VANGUARD CAPITAL MANAGEMENT LLC | $7.3M | 1,494,611 |
| GEODE CAPITAL MANAGEMENT, LLC | $4.4M | 910,866 |
| Siren, L.L.C. | $3.5M | 720,720 |
Companies Similar to FHTX
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
BICYCLE THERAPEUTICS PLC
Invivyd, Inc.
AGIOS PHARMACEUTICALS, INC.
Kymera Therapeutics, Inc.
UroGen Pharma Ltd.
Syndax Pharmaceuticals Inc
Kura Oncology, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put FHTX on your watchlist
Track score changes the day Foghorn Therapeutics Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is FHTX a good stock to buy?
13F Pro's AI-powered analysis of Foghorn Therapeutics Inc. (FHTX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for FHTX are available on the FHTX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. FHTX is classified as a small company.
Which hedge funds own FHTX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling FHTX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Foghorn Therapeutics Inc.'s investment landscape.